# POLO (NCT02184195)

> Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

No report yet. It can be ordered.

- Drugs tested: olaparib
- Indication: germline BRCA-mutated metastatic pancreatic cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02184195
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Germline BRCA1/2 Mutations and; Metastatic Adenocarcinoma of the Pancreas
- Interventions: Olaparib; Olaparib; Placebo; Placebo
- Enrollment: 154
- Primary outcome: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)

## Indexed commentary on POLO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 109
- Podcasts: 32
- YouTube: 25
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=polo-nct02184195

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02184195", "email": "<work email>"}; the inbox owner confirms by the emailed link.